In the SGLT2 inhibitor trials in T2DM and chronic stable coronary disease, patients were excluded if they had suffered an acute MI within 2 months4 and few were enrolled within 1 year of an acute MI.5 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.